ESC Premium Access

Natriuretic effect of 2 weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function: results of the DAPASALT trial

Congress Presentation

About the speaker

Professor Hiddo Heerspink

University Medical Centre Groningen, Groningen (Netherlands (The))
5 presentations
0 follower

7 more presentations in this session

Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial.

Speaker: Doctor G. Ferrannini (Stockholm, SE)


Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis

Speaker: Professor H. Colhoun (Edinburgh, GB)


Direct effects of canagliflozin on human myocardial redox signalling: a novel role for SGLT1 inhibition

Speaker: Doctor H. Kondo (Oxford, GB)


Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME

Speaker: Professor S. Verma (Toronto, CA)


The effects of empagliflozin on arterial stiffness, endothelial function and ventriculoarterial coupling in type 2 diabetes mellitus: 1 year follow up

Speaker: Doctor I. Ikonomidis (Athens, GR)


Access the full session

Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy

Speakers: Professor H. Heerspink, Doctor G. Ferrannini, Professor H. Colhoun, Doctor H. Kondo, Professor S. Verma...

About the event


ESC CONGRESS 2020 - The Digital Experience

28 August - 1 September 2020

Sessions Presentations

Related content

Open Access

GUIDE-HF - Panel discussion.

27 August 2021

ESC Premium Access

A closer look at heart failure drugs: particular benefits and problems.

27 August 2021

ESC Premium Access

The practicalities of drug treatment in heart failure - Chat Moderator.

27 August 2021

ESC 365 is supported by

logo Novo Nordisk